Category: Mission in Action

February 8, 2019

Geneva Launches CMIRR

The Uniformed Services University (USU) recently issued a Cooperative agreement to Geneva to facilitate the execution of the Collaboratory for Musculoskeletal Injury Rehabilitation Research (CMIRR). CMIRR is a four-year, $15M program funded by the Defense Health Agency (DHA), with the purpose of improving a rehabilitative approach to caring for military service members with musculoskeletal injury

Read more
September 18, 2018

Fort Bragg Research Institute

The Fort Bragg Research Institute (FBRI) originated from the recognized need to link the vast infrastructure of science and technology regionally available to Womack Army Medical Center (WAMC) with the growing needs of operational readiness for Fort Bragg, NC. Areas of research interest include biomarker discovery for mild traumatic brain injury, machine learning to assist medics

Read more
June 21, 2018

4D Bio3 Program

The 4-Dimensional Bioprinting, Biofabrication, and Biomanufacturing (4D Bio3) Program is a five-year program funded by the Defense Health Program (DHP), with the purpose of promoting the development and application of advanced bioprinting, biofabrication, and biomanufacturing technologies for research pursuant to Department of Defense (DoD) priorities and ultimately for translation to clinical medical defense care and training solutions.

Read more
June 6, 2018

Geneva Launches Fort Bragg Research Institute Program

Geneva is proud to announce the launch of its newest program, the Fort Bragg Research Institute (FBRI). The FBRI was established to link the infrastructure of science and technology regionally available to Womack Army Medical Center (WAMC) and the increasing needs of operational readiness at Fort Bragg, NC.

Read more
November 16, 2017

Exxell Bio, Inc. Teams with Geneva in Vaccine Development Collaboration

Exxell BIO, Inc. joins consortium in collaboration with Geneva, Thomas Jefferson University, USAMRIID, IDT Biologika, and IDRI for preparation and vaccine formulation testing for protection against the Ebola, Sudan, Marburg, and Lassa fever viruses. These deadly viruses, categorized as hemorrhagic fever viruses, display varying symptoms that typically appear 2-21 days after exposure, and can include

Read more
March 27, 2017

Geneva Teams with Phelix Therapeutics and USAMRIID

Phelix Therapeutics is launching a collaboration with The Geneva Foundation and The United States Army Medical Research Institute of Infectious Diseases (USAMRIID) for continued research of a treatment for SARS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome) via Phelix’s “novel viral fusion inhibitors for treating SARS/MERS coronaviruses”. SARS and MERS are coronaviruses

Read more
September 1, 2016

Geneva Partners with the Jonas Center

The Jonas Center for Nursing and Veterans Healthcare announced a partnership to support The Geneva Foundation’s first scholarship for nursing research to advance military medicine. The scholarship will fund a Johns Hopkins School of Nursing doctoral candidate whose goal is to transform the diagnosis process for Post-Traumatic Stress Disorder (PTSD) – an area of scientific study

Read more